August 18, 2022
Life Sciences
  • The Food and Drug Administration (FDA) approved Bluebird Bio Inc.’s Zynteglo gene therapy. The approval gives patients suffering from a rare genetic blood disorder called beta-thalassemia a possible cure, at a hefty price. Bluebird, which has priced the treatment at $2.8 million per patient, said it would pay back private and commercial payers up to 80% of the cost if it’s no longer effective two years after a patient takes it. (Article here)